Corbus Pharmaceuticals Holdings Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Corbus Pharmaceuticals Holdings Inc
Access all reports
Corbus Pharmaceuticals Holdings Inc. is a biopharmaceutical company that specializes in precision oncology. The company's research and development efforts focus on innovative treatments that target well-understood biological pathways related to cancer. Corbus' pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) designed to target the Nectin-4 protein on cancer cells, and CRB-601, an anti-integrin monoclonal antibody that inhibits the activation of TGFβ on cancer cells. These treatments are intended to combat serious illnesses by offering new therapeutic options for patients. The company is headquartered in Norwood, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Corbus Pharmaceuticals Holdings Inc
Corporate Presentation
Corbus Pharmaceuticals Holdings Inc
Corporate Presentation
Corbus Pharmaceuticals Holdings Inc
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
CRBP
Country
🇺🇸 United States